Aveanna downgraded by Credit Suisse with a new price target

Fourth Quarter Revenue was $519.9 million, an 8.6% increase over the prior year period Gross margin increased 15.7% to $171.7 million compared to Q4 2023 Fourth Quarter Net income was $29.2 million compared to net loss of $25.7 million for the comparable prior year period Adjusted Net income was $11.1 million, an increase of $14.3 million compared to Q4 2023 Adjusted EBITDA for Q4 2024 was $55.2 million, a 42.8% increase as compared to Q4 2023Full Year 2025 Revenue guidance between $2.10 - $2.12 billion Full Year 2025 Adjusted EBITDA guidance between $190 - $194 million ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:A

ATLANTA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 13, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13750192. The replay will be available until March

ATLANTA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that its management team will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. Management will present at 10:30 a.m. PST followed by 1x1 investor meetings on the same day, January 15, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company's website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call. About Aveanna Healthcare Aveanna Healthcare is headquarte

JP Morgan downgraded Aveanna from Neutral to Underweight

UBS initiated coverage of Aveanna with a rating of Sell and set a new price target of $1.50

Raymond James downgraded Aveanna from Strong Buy to Mkt Perform

4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

DEFA14A - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

DEF 14A - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

ATLANTA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Brent Layton to serve as a Class III director of the Board of Directors of Aveanna Healthcare Holdings Inc., and additionally as a member of the Audit Committee of the Board, effective November 1, 2024. "I am delighted to announce the appointment of Brent Layton to our Aveanna Board of Directors. Brent brings a wealth of healthcare knowledge from over 20 years of leadership at Centene Corporation. Brent's experience working with state and feder

ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Jerry Perchik to serve as Chief Legal Officer and Secretary, effective April 29, 2024. "I am pleased to announce the appointment of Jerry to the Chief Legal Officer and Secretary role. Jerry has a strong background in corporate law and a wealth of healthcare industry and regulatory experience. I have known Jerry for more than a decade and have great trust in his leadership and counsel. It is a pleasure to welcome Jerry to our Aveanna family, and

ATLANTA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Matt Buckhalter to serve as Chief Financial Officer and continuing in the role of Principal Financial Officer, effective January 1, 2024. Mr. Buckhalter was appointed to serve as Interim Chief Financial Officer and Principal Financial Officer in July, 2023. "I am pleased to announce the promotion of Matt to the Chief Financial Officer position. Matt has provided strong financial leadership and continuity as we build on our recent successes to t

Fourth Quarter Revenue was $519.9 million, an 8.6% increase over the prior year period Gross margin increased 15.7% to $171.7 million compared to Q4 2023 Fourth Quarter Net income was $29.2 million compared to net loss of $25.7 million for the comparable prior year period Adjusted Net income was $11.1 million, an increase of $14.3 million compared to Q4 2023 Adjusted EBITDA for Q4 2024 was $55.2 million, a 42.8% increase as compared to Q4 2023Full Year 2025 Revenue guidance between $2.10 - $2.12 billion Full Year 2025 Adjusted EBITDA guidance between $190 - $194 million ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:A

ATLANTA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 13, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13750192. The replay will be available until March

Third Quarter Revenue was $509.0 million, a 6.5% increase over the prior year period Gross margin increased 8.4% to $159.7 million, compared to Q3 2023 Third Quarter Net loss was $42.8 million, compared to net loss of $102.4 million in the comparable prior year period Adjusted Net income was $4.6 million, an increase of $9.3 million over the comparable prior year period Adjusted EBITDA was $47.8 million, a 32.2% increase as compared to the prior year periodFull Year 2024 Revenue guidance raised to approximately $2.0 billion Full Year 2024 Adjusted EBITDA guidance raised to greater than $168 million ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH)

SC 13G - Aveanna Healthcare Holdings, Inc. (0001832332) (Subject)

SC 13G - Aveanna Healthcare Holdings, Inc. (0001832332) (Subject)